Equity Profile

CTMX

CytomX Therapeutics, Inc.

Health CareBiotechnology$783.7M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTMX Q2-2026 Earnings Preview

Context

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. Operating in the health care sector, it specializes in a unique approach to targeting cancer cells while minimizing damage to healthy tissue, which is crucial in the ongoing fight against cancer.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.67%

Avg Stock Reaction

+21.44%

Last Quarter Recap

In Q1-2026, CytomX reported an EPS of -$0.10, outperforming expectations by 29.58%. However, the stock fell 3.15% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are uncertain about CytomX's upcoming earnings, especially given the lack of specific guidance and analyst estimates. The market is likely weighing the company's recent performance against its future potential.

Bull Case

If CytomX can demonstrate significant progress in its clinical trials or partnerships, it could lead to strong revenue growth and a positive market reaction.

Bear Case

Conversely, if the company fails to show advancements in its drug development or reports disappointing financials, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can the company report regarding its cancer therapies?

Investors will be keen to hear about any progress in clinical trials or partnerships that could impact future revenue.

How does management view the competitive landscape in the biotechnology sector?

Understanding management's perspective on competition could provide insights into the company's strategy and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CytomX's potential for significant advancements in its clinical trials this quarter, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The company's recent EPS surprise of +29.58% indicates potential for better-than-expected performance.

Options pricing suggests a higher volatility expectation, which could reflect investor confidence in upcoming news.

Key Risk

If the company announces a major partnership or breakthrough in its drug pipeline, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether CytomX can demonstrate tangible progress in its drug development pipeline.

Bull Confirmed If

A reported EPS of -$0.05 or better would confirm the bull case, indicating improved financial performance.

Bear Confirmed If

An EPS worse than -$0.15 would support the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±37.5%

Historical Avg

±23.1%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±37.5% while CTMX has averaged ±23.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

37.6%

Calls (36K)P/C Ratio: 0.03Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CytomX beats expectations, history suggests the stock could rise by an average of 25.20%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction as investors reassess growth prospects.

Miss

A miss on earnings could lead to a decline of around 15.16%, reflecting investor disappointment and concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key cancer therapies.
2Any new partnerships or collaborations that could enhance the company's market position.
3Management's outlook on future revenue growth and market opportunities.
4Insights into competitive pressures and how CytomX plans to address them.
5Details on any changes to the company's strategic direction or focus areas.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CTMX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+61.67%

Avg Stock Reaction

+21.44%

Last Quarter Recap

In Q1-2026, CytomX reported an EPS of -$0.10, outperforming expectations by 29.58%. However, the stock fell 3.15% the following day, indicating mixed investor sentiment.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If CytomX can demonstrate significant progress in its clinical trials or partnerships, it could lead to strong revenue growth and a positive market reaction.

Bear Case

Conversely, if the company fails to show advancements in its drug development or reports disappointing financials, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can the company report regarding its cancer therapies?

Investors will be keen to hear about any progress in clinical trials or partnerships that could impact future revenue.

How does management view the competitive landscape in the biotechnology sector?

Understanding management's perspective on competition could provide insights into the company's strategy and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating CytomX's potential for significant advancements in its clinical trials this quarter, which could lead to a more favorable outlook than currently anticipated.

Supporting Evidence

The company's recent EPS surprise of +29.58% indicates potential for better-than-expected performance.

Options pricing suggests a higher volatility expectation, which could reflect investor confidence in upcoming news.

Key Risk

If the company announces a major partnership or breakthrough in its drug pipeline, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether CytomX can demonstrate tangible progress in its drug development pipeline.

Bull Confirmed If

A reported EPS of -$0.05 or better would confirm the bull case, indicating improved financial performance.

Bear Confirmed If

An EPS worse than -$0.15 would support the bear case, suggesting ongoing challenges in profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±37.5%

Historical Avg

±23.1%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.

Options are pricing ±37.5% while CTMX has averaged ±23.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

37.6%

Calls (36K)P/C Ratio: 0.03Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CytomX beats expectations, history suggests the stock could rise by an average of 25.20%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see a muted reaction as investors reassess growth prospects.

Miss

A miss on earnings could lead to a decline of around 15.16%, reflecting investor disappointment and concerns about the company's future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key cancer therapies.
2Any new partnerships or collaborations that could enhance the company's market position.
3Management's outlook on future revenue growth and market opportunities.
4Insights into competitive pressures and how CytomX plans to address them.
5Details on any changes to the company's strategic direction or focus areas.